Thyroid hormone has been shown to stimulate bone résorption. Both endogenous hyperthyroidism and exogenous thyroxine suppressive therapy have been associated with reduction in bone mineral density (BMD), but the patholophysiology of thyroxine-induced bone loss is not well understood. First we studied the effect of L-T4 (0.1-0.3 u,g/g body weight ip/day) on bone turnover in rats by measuring regional BMDs and osteocalcin mRNA. Next we determined whether antiresorptive agents (calcitonin 1 |xU/g ip/day or sodium etidronate given cyclically at 10 u.g/g po for 3 consecutive days out of every week) could prevent bone loss. Groups of 10 male Sprague-Dawley rats each weighing 320-350 g were studied before and after 3 weeks of treatment. L-T4 treatment resulted in reduction in BMDs in the lumbar spine, tail, and femur as measured by dual energy X-ray absorptiometry, but there was no correlation with the dosage of L-T4 or the serum T4 level. Treatment with sodium etidronate or calcitonin alone did not alter the regional BMD. Cyclical sodium etidronate, but not calcitonin, was able to prevent the bone loss induced by L-T4 treatment. L-T4 caused a dose-dependent increase in femur osteocalcin mRNA concentration. Treatment with calcitonin resulted in 50% reduction of osteocalcin mRNA, but sodium etidronate had no effect. In conclusion, cyclical sodium etidronate prevents bone loss induced by exogenous L-T4 in rats and may be useful in preventing osteoporosis in patients given long term TSH-suppressive doses of thyroxine therapy.
INTRODUCTION

THYROID
HORMONES have been shown to regulate normal bone maturation, as evidenced by the fact that hyperthyroidism or hypothyroidism in childhood is associated with abnormal growth and stature (1, 2) . In adults, recent evidence shows that an excess of thyroid hormones affects the remodeling system in cortical and trabecular bone and may contribute to the development of osteoporosis (3) . Thyroid hormone increases calcium release from fetal rat long bone cultures and increases osteoblast number and activity (4) . In vivo, thyroid hormone also stimulates osteoblast activity (5) . In hyperthyroidism the activation frequency of bone remodeling is increased, which results in an accelerated bone résorption and a concomitant increase in bone formation, with a marked shortening of both resorptive and formative phases of the remodeling cycle (6) .
This results in a net reduction of bone mass. A number of studies confirmed that patients suffering from hyperthyroidism had lower bone mineral content at both cortical and trabecular bone (7) . Furthermore, decrease in bone mineral densities (BMD) was similarly observed in subjects on physiologic or suppressive dosage of L-thyroxine treatment in some studies but not in others (8, 9) .
It is still debatable whether adjunctive therapy is warranted to prevent rapid bone loss during thyroxine therapy, especially in postmenopausal women and older individuals who present with symptomatic or severe bone loss. Antiresorptive agents such as calcitonin and the diphosphonates that act by inhibiting osteoclast activity have been shown to prevent bone loss in patients with postmenopausal osteoporosis (10) (11) (12) (13) (14) . The accuracy and precision of estimating BMD in total animal in vivo were found to be 1%. An ultrastable X-ray source, operated at 100 kV and 1 mA, was used to provide the X-ray beam that was then K-edged (46.8 keV) by the samarium filtering module. This resulted in production of monochromatic X-ray beams with two energies at approximately 45 GAGGGTCCTCATGGT-3') was synthesized corresponding to the complementary sequences of the bases 1-20 of the rat osteocalcin cDNA (16 
Thyroidfunction
Blood was collected at termination of the experiment by cardiac puncture, and sera were stored at -20°C until batch (Table 4) .
DISCUSSION
Our present data demonstrated that in rats exogenous thyroid hormone produced bone loss in the spine and femoral bones simulating its action in humans. Using the rat model for studies of bone metabolism is well documented, and models of human pathologies like aging (17) , estrogen depletion (18) , immobilization (19) , and dietary calcium deficiency (20) have been established. The use of a noninvasive technique such as DEXA 0-6 kb-^i fw W w for determination of BMD has also been varified in rats, with data correlating strongly with those obtained by ashing (21, 22) .
The pattern of bone loss in this rat model is similar to that observed in humans. It has been reported that thyroid hormone induced bone loss in appendicular bone in premenopausal women (23) , while in postmenopausal subjects bone loss is observed in both appendicular and axial bone (24) . The overall pattern of bone loss induced by exogenous thyroid hormone therapy is similar to that observed in patients with endogenous hyperthyroidism (25) . Ongphiphadhanakul et al performed similar study and demonstrated that excessive L-T4 therapy induced bone loss in the rat femur, except that they did not observe any change in the rat spine (26) .
The pharmacopathology of thyroid hormone-induced bone loss is not well understood. Although both T3 and T4 dose dependently stimulate 45Ca release from cultured fetal rat long bones in vitro (4), the effect is biphasic in mouse; higher doses of T3 inhibit rather than stimulate calcium release (27) . We observed that in patients on physiologic dose of L-T4 replacement with normal thyroid function, the Z score of the femoral neck correlated negatively with the serum-free thyroxine index (FTI) (8) (28) .
Thyroid hormone exerts its bone résorption activity via its action on the osteoblasts. Nuclear thyroid hormone receptors have been identified in rat osteosarcoma cell lines UMR-106 (29) and mouse osteoblast-like cell line MC3 T3-E1 (30) . Also, human osteoblastic cell line MG63 has been shown to express T3 receptor mRNA (31) . Thyroid hormone receptors have not been identified in osteoclasts and there was no effect of T3 on bone résorption by isolated osteoclasts (30) . It is thus believed that the effect of thyroid hormone on osteoclastic bone résorption is indirectly mediated, and the osteoblast acts as the intermediary cell, thus resulting in a high turnover bone loss.
In this present rat model, we observed a positive relationship between serum T4 level and osteocalcin mRNA expression. This finding has also been reported previously (32) . Osteocalcin is a noncollagenous bone matrix protein synthesized by osteoblasts and has been a useful clinical marker for increased bone turnover (33) . Serum osteocalcin is increased in hyperthyroid patients (34) and in patients with multinodular goitre with suppressed TSH levels (35) . We also observed in patients on long-term L-T4 suppressive therapy with elevated serum osteocalcin level, there was a negative correlation between the serum osteocalcin and the Z score of the regional BMDs (9) . Thus estimation of osteocalcin may be a sensitive way of identifying which patient is at particular high risk of developing osteoporosis. However, our study has not addressed how thyroid hormone increases steady-state osteocalcin mRNA. Osteocalcin transcription is stimulated by l,25-(OH)2 D3 (36) , but thyroid hormone has not been shown to increase osteocalcin transcription in transfection studies (37) . The action of thyroid hormone probably does not depend on vitamin D as hyperthyroidism is associated with a reduction in 1,25-(OH)2 D3 levels both in man (38) and rats (39) .
In this study we (40) . They inhibit bone résorption by binding to bone surfaces and cause injury to the osteoclasts. Calcitonin, on the other hand, inhibits osteoclastic activity and motility ad reduces their cell number (41) . The effect of these agents on bone formation is complex and it has not yet been established for certain whether they exert any effect on the osteoblast. For example, studies of the long-term effect of calcitonin on bone remodeling suggest that it lengthens the formation phase at the expense of the reversal phase between résorption and formation (42) . This might be due to an indirect effect via osteoclasts or to a direct effect via osteoblasts. So far calcitonin receptor has only been found in the osteoclast but not osteoblast (43) . Thus the observed inhibitory effect of calcitonin on osteocalcin gene expression is probably via an intermediary effect on osteoclasts, thus decreasing bone turnover. Although treatment of the thyrotoxic rats with calcitonin negated the effect of thyroxine on steady-state osteocalcin mRNA, the actions of L-T4 and calcitonin on osteocalcin gene transcription are probably at different levels and require further elucidation. It is also of interest that despite the effectiveness of sodium etidronate in preventing bone loss, it has no effect on L-T4-induced elevation of osteocalcin mRNA concentration. Ongphiphadehanakul similarly reported that sodium etidronate was able to prevent the bone loss but not the increase in tartrate-resistant acid phosphatase induced by L-T4 (44) .
Both calcitonin and sodium etidronate have been proven to be effective in the treatment of postmenopausal osteoporosis (10) (11) (12) (13) . Thus it was surprising to observe in this study that calcitonin is ineffective in preventing bone loss induced by L-T4, as calcitonin has in fact been demonstrated to be more effective in those osteoporotic patients with "high" turnover than in those with "low" turnover, as defined biochemically by an elevation of osteocalcin (45) . The use of calcitonin in treatment high turnover bone loss is well illustrated by its effectiveness in treating Paget's disease (46) . Thus, the role of antiresorptive agents in preventing thyroid hormone induced bone loss needs to be confirmed in human studies.
In conclusion, we have established a rat model of thyroid hormone induced bone loss. The diphosphonate agent, sodium etidronate, but not calcitonin, was able to prevent L-T4-induced bone loss in the present model.
